• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Establishment Labs Holdings Inc.

    2/9/24 5:00:58 PM ET
    $ESTA
    Industrial Specialties
    Health Care
    Get the next $ESTA alert in real time by email
    SC 13G 1 form13g_chaconquiros123123.htm SC 13G Document


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. 5)*

    Establishment Labs Holdings Inc.
    (Name of Issuer)
    Common Shares, no par value
    (Title of Class of Securities)
    G31249 108
    (CUSIP Number)
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ¨
    Rule 13d-1(b)
    ¨
    Rule 13d-1(c)
    x
    Rule 13d-1(d)
    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).








    CUSIP No. G31249 108
    1. Names of Reporting Persons.
    Juan Jose Chacon Quiros
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ¨
    (b) ¨
    3. SEC Use Only
    4. Citizenship or Place of Organization Costa Rica
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5. Sole Voting Power 1,439,943 (See Item 4(a) below)
    6. Shared Voting Power 0
    7. Sole Dispositive Power 1,439,943 (See Item 4(a) below)
    8. Shared Dispositive Power 0
    9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,439,943 (See Item 4(a) below)
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    11. Percent of Class Represented by Amount in Row (9) 5.6% (See Item 4(b) below)
    12. Type of Reporting Person (See Instructions)
    IN






    Item 1(a) Name of Issuer:
        Establishment Labs Holdings Inc.
    Item 1(b) Address of Issuer’s Principal Executive Offices:
        Building B15 and 25
        Coyol Free Zone
        Alajuela
        Costa Rica
    Item 2 (a) Name of Person Filing:
        Juan Jose Chacón Quirós
    Item 2 (b) Address of Principal Business Office or, if none, Residence:
        c/o Establishment Labs Holdings Inc.
        Building B15 and 25
        Coyol Free Zone
        Alajuela
        Costa Rica
    Item 2 (c) Citizenship:
        Juan Jose Chacón Quirós is a citizen of Costa Rica.
    Item 2 (d) Title of Class of Securities:
        Common Shares, no par value
    Item 2 (e) CUSIP Number:
        G31249 108
    Item 3.    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    Not applicable.
    Item 4.     Ownership
        (a)    Amount beneficially owned:    
    As of December 31, 2023, (i) 196,856 Common Shares were held of record by Juan Jose Chacon Quiros, (ii) Mr. Chacon Quiros has the right to acquire 114,823 Common Shares within 60 days of December 31, 2023 upon the exercise of stock options and (iii) 1,128,264 Common Shares were held of record by Sariel LLC, of which Mr. Chacon Quiros is a shareholder and over which he has voting and dispositive power.



        (b)    Percent of class: 5.6%
    The ownership percentage above is calculated based on 25,808,260 Common Shares outstanding as of November 7, 2023, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023.
        (c)    Number of shares as to which the person has:
            (i)    Sole power to vote or direct the vote:    1,439,943 shares
            (ii)    Shared power to vote or direct the vote:     0 shares
            (iii)    Sole power to dispose or to direct the disposition of:    1,439,943 shares
            (iv)    Sole power to dispose or to direct the disposition of:    0 shares
    Item 5.     Ownership of 5 Percent or Less of a Class
        Not applicable.
    Item 6.     Ownership of More than 5 Percent on Behalf of Another Person
        Not applicable.
    Item 7.     Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
        Not applicable.
    Item 8.     Identification and Classification of Members of the Group
        Not applicable.
    Item 9.     Notice of Dissolution of Group
        Not applicable.
    Item 10.     Certifications
        Not applicable.




    SIGNATURES
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    Date: February 9, 2024

    /s/ Juan Jose Chacon Quiros    
    Juan Jose Chacon Quiros





    Get the next $ESTA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ESTA

    DatePrice TargetRatingAnalyst
    5/16/2025$62.00Buy
    BTIG Research
    5/14/2025$48.00Hold → Buy
    Needham
    4/14/2025Hold
    Needham
    5/22/2024$60.00Buy → Neutral
    Citigroup
    8/31/2023$75.00Overweight
    JP Morgan
    6/29/2023$79.00Buy
    Citigroup
    10/14/2022$90.00Overweight
    Stephens
    10/13/2022$70.00Buy
    Mizuho
    More analyst ratings

    $ESTA
    SEC Filings

    See more
    • Establishment Labs Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)

      6/12/25 1:00:50 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)

      5/27/25 4:12:22 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs Holdings Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Other Events, Financial Statements and Exhibits

      8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)

      5/22/25 5:10:52 PM ET
      $ESTA
      Industrial Specialties
      Health Care

    $ESTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lewin Nicholas Sheridan bought $54,073 worth of shares (2,000 units at $27.04), increasing direct ownership by 0.19% to 1,064,888 units (SEC Form 4)

      4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

      12/15/23 7:59:37 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Lewin Nicholas Sheridan bought $110,000 worth of shares (5,000 units at $22.00) (SEC Form 4)

      4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

      11/21/23 8:00:55 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Denhoy Raj bought $49,972 worth of shares (2,250 units at $22.21), increasing direct ownership by 38% to 8,112 units (SEC Form 4)

      4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

      11/20/23 8:00:42 AM ET
      $ESTA
      Industrial Specialties
      Health Care

    $ESTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Large owner Jw Asset Management, Llc

      4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

      7/9/25 4:01:11 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Large owner Jw Asset Management, Llc

      4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

      7/7/25 4:05:59 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Large owner Jw Asset Management, Llc sold $430,486 worth of shares (9,700 units at $44.38) (SEC Form 4)

      4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

      7/2/25 4:01:08 PM ET
      $ESTA
      Industrial Specialties
      Health Care

    $ESTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Establishment Labs to Announce Second Quarter 2025 Financial Results on August 7

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2025, before the market opens on Thursday, August 7, 2025, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (416) 764 8646 (U.S. and Canada) or +1 (888) 396 8049 (International) and use conference ID number 13750829. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establ

      7/25/25 8:00:00 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs Hosting Investor Day on June 12

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, will host its previously announced analyst and investor event in New York City on June 12, 2025 beginning at 1pm ET. A live and archived webcast of presentations and Q&A sessions on June 12 will be available on the "Investors" section of the Establishment Labs website at www.establishmentlabs.com. In-person attendance at the event is limited and requires advanced registration. Please email: [email protected] for further information. About Establishment Labs Establishment Labs Holdings Inc. is

      6/11/25 7:07:00 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs to Present at Jefferies Global Healthcare Conference

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in the Jefferies Global Healthcare Conference. Peter Caldini, Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, are scheduled to present in a fireside chat on Wednesday, June 4, 2025 at 7:35 a.m. ET. A live webcast of the presentation will be available on the Establishment Labs investor relations website at https://investors.establishmentlabs.com/. Archived versions of the webcasts will be available on the same website following the completion of the e

      6/3/25 4:30:00 PM ET
      $ESTA
      Industrial Specialties
      Health Care

    $ESTA
    Leadership Updates

    Live Leadership Updates

    See more
    • Establishment Labs Appoints Peter Caldini as Chief Executive Officer

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today the appointment of Peter Caldini as Chief Executive Officer effective May 7, 2025. Mr. Caldini has served as Interim CEO since March 1, 2025, when Establishment Labs' Founder and previous CEO Juan José Chacón-Quirós retired from the role. "After an extensive search process, it was clear that with his deep operational, commercial, and financial skills, Peter is the ideal person to lead Establishment Labs," commented Nick Lewin, Chairman of the Board of Establishment Labs. "We have a vision

      5/7/25 4:00:00 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs Announces CEO Transition

      Peter Caldini to become Interim CEO effective March 1, 2025 Establishment Labs also announces preliminary unaudited fourth quarter revenue in line with recent guidance Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness in breast aesthetics and reconstruction, announced today that after twenty years as Chief Executive Officer (CEO), Juan José Chacón-Quirós has decided to retire as CEO, effective March 1, 2025. Peter Caldini, currently President of Establishment Labs, will serve as Interim CEO after that date. Mr. Chacón-Quirós will continue with Establishment Labs as both a board member and an active

      1/13/25 8:00:00 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs Announces Appointment of Jeff Ehrhardt as General Manager of North America

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today that Jeff Ehrhardt has joined the company as General Manager of North America. After having spent over 25 years at Allergan Aesthetics, an Abbvie Company, Mr. Ehrhardt joins Establishment Labs with responsibilities including the anticipated launch of Motiva implants in the U.S. later this year. "Jeff is the ideal person to introduce Motiva to the United States," said Juan José Chacón-Quirós, CEO and Founder of Establishment Labs. "Just as we have changed the standard for breast augmentat

      5/1/24 8:30:00 AM ET
      $ESTA
      Industrial Specialties
      Health Care

    $ESTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Establishment Labs Holdings Inc.

      SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

      11/12/24 12:54:20 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Establishment Labs Holdings Inc.

      SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

      11/12/24 9:03:38 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Establishment Labs Holdings Inc. (Amendment)

      SC 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

      2/14/24 4:51:40 PM ET
      $ESTA
      Industrial Specialties
      Health Care

    $ESTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on Establishment Labs with a new price target

      BTIG Research initiated coverage of Establishment Labs with a rating of Buy and set a new price target of $62.00

      5/16/25 8:05:11 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs upgraded by Needham with a new price target

      Needham upgraded Establishment Labs from Hold to Buy and set a new price target of $48.00

      5/14/25 8:49:26 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Needham initiated coverage on Establishment Labs

      Needham initiated coverage of Establishment Labs with a rating of Hold

      4/14/25 7:48:56 AM ET
      $ESTA
      Industrial Specialties
      Health Care

    $ESTA
    Financials

    Live finance-specific insights

    See more
    • Establishment Labs to Announce Second Quarter 2025 Financial Results on August 7

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2025, before the market opens on Thursday, August 7, 2025, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (416) 764 8646 (U.S. and Canada) or +1 (888) 396 8049 (International) and use conference ID number 13750829. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establ

      7/25/25 8:00:00 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs Reports First Quarter 2025 Financial Results

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2025. First Quarter Highlights and Outlook First quarter worldwide revenue of $41.4 million, including $6.2 million of Motiva sales in the United States. 2025 revenue guidance maintained at $205 million to $210 million, year over year growth of 23%–26%. First quarter gross margin of 67.2% compared to 65.6% in the year-ago period. First quarter loss from operations was $16.9 million compared to a loss of $8.8 million in the ye

      5/7/25 4:00:00 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs to Announce First Quarter 2025 Financial Results on May 7

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2025, after the market closes on Wednesday, May 7, 2025, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or +1 (201) 689-8037 (International) and use conference ID number 13750827. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establis

      4/24/25 8:00:00 AM ET
      $ESTA
      Industrial Specialties
      Health Care